Proto-Oncogene Proteins p21(ras)
"Proto-Oncogene Proteins p21(ras)" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cellular proteins encoded by the H-ras, K-ras and N-ras genes. The proteins have GTPase activity and are involved in signal transduction as monomeric GTP-binding proteins. Elevated levels of p21 c-ras have been associated with neoplasia. This enzyme was formerly listed as EC 3.6.1.47.
Descriptor ID |
D016283
|
MeSH Number(s) |
D08.811.277.040.330.300.400.500.600 D12.644.360.525.500.600 D12.776.157.325.515.500.600 D12.776.476.525.500.600 D12.776.624.664.700.200
|
Concept/Terms |
Proto-Oncogene Proteins p21(ras)- Proto-Oncogene Proteins p21(ras)
- p21 c-ras
- c-ras, p21
- p21 c ras
- p21(c-ras)
- ras Proto-Oncogene Protein p21
- ras Proto Oncogene Protein p21
- Proto-Oncogene Proteins c-ras
- Proteins c-ras, Proto-Oncogene
- Proto Oncogene Proteins c ras
- c-ras, Proto-Oncogene Proteins
- Proto-Oncogene Protein ras
- Proto Oncogene Protein ras
- ras, Proto-Oncogene Protein
- ras Proto-Oncogene Product p21
- ras Proto Oncogene Product p21
- c-ras Proteins
- c ras Proteins
- p21(ras)
- Proto-Oncogene Protein p21(ras)
Proto-Oncogene Protein p21(c-Ha-ras)- Proto-Oncogene Protein p21(c-Ha-ras)
- p21 c-Ha-ras
- c-Ha-ras, p21
- p21 c Ha ras
- p21(c-Ha-ras)
- p21 c-H-ras
- c-H-ras, p21
- p21 c H ras
- c-Ha-ras p21
- c Ha ras p21
- p21, c-Ha-ras
Proto-Oncogene Protein p21(c-Ki-ras)- Proto-Oncogene Protein p21(c-Ki-ras)
- p21 c-Ki-ras
- c-Ki-ras, p21
- p21 c Ki ras
- p21(c-Ki-ras)
- p21 c-K-ras
- c-K-ras, p21
- p21 c K ras
- c-Ki-ras p21
- c Ki ras p21
- p21, c-Ki-ras
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins p21(ras)".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins p21(ras)".
This graph shows the total number of publications written about "Proto-Oncogene Proteins p21(ras)" by people in this website by year, and whether "Proto-Oncogene Proteins p21(ras)" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 2 | 0 | 2 |
1995 | 1 | 0 | 1 |
1996 | 1 | 1 | 2 |
1997 | 0 | 1 | 1 |
1998 | 1 | 3 | 4 |
1999 | 0 | 1 | 1 |
2000 | 0 | 2 | 2 |
2001 | 0 | 2 | 2 |
2002 | 1 | 1 | 2 |
2003 | 2 | 3 | 5 |
2004 | 0 | 1 | 1 |
2005 | 1 | 4 | 5 |
2006 | 0 | 3 | 3 |
2007 | 1 | 2 | 3 |
2008 | 4 | 6 | 10 |
2009 | 5 | 13 | 18 |
2010 | 4 | 14 | 18 |
2011 | 4 | 25 | 29 |
2012 | 5 | 24 | 29 |
2013 | 9 | 26 | 35 |
2014 | 6 | 23 | 29 |
2015 | 13 | 24 | 37 |
2016 | 13 | 17 | 30 |
2017 | 26 | 17 | 43 |
2018 | 15 | 8 | 23 |
2019 | 17 | 15 | 32 |
2020 | 18 | 16 | 34 |
2021 | 19 | 8 | 27 |
2022 | 5 | 26 | 31 |
2023 | 13 | 29 | 42 |
2024 | 2 | 10 | 12 |
To return to the timeline,
click here.
Below are the most recent publications written about "Proto-Oncogene Proteins p21(ras)" by people in Profiles.
-
Activation of endogenous retroviruses and induction of viral mimicry by MEK1/2 inhibition in pancreatic cancer. Sci Adv. 2024 Mar 29; 10(13):eadk5386.
-
An atlas of epithelial cell states and plasticity in lung adenocarcinoma. Nature. 2024 Mar; 627(8004):656-663.
-
Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax. Blood Adv. 2024 Feb 27; 8(4):927-935.
-
The Vitamin C Enantiomers Possess a Comparable Potency in the Induction of Oxidative Stress in Cancer Cells but Differ in Their Toxicity. Int J Mol Sci. 2024 Feb 22; 25(5).
-
A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer. Clin Cancer Res. 2024 02 16; 30(4):655-662.
-
Early elevations of RAS protein level and activity are critical for the development of PDAC in the context of inflammation. Cancer Lett. 2024 Apr 01; 586:216694.
-
Reconstitution of human PDAC using primary cells reveals oncogenic transcriptomic features at tumor onset. Nat Commun. 2024 Jan 27; 15(1):818.
-
Inhibition of ADAM9 promotes the selective degradation of KRAS and sensitizes pancreatic cancers to chemotherapy. Nat Cancer. 2024 Mar; 5(3):400-419.
-
Effects of KRAS Genetic Interactions on Outcomes in Cancers of the Lung, Pancreas, and Colorectum. Cancer Epidemiol Biomarkers Prev. 2024 01 09; 33(1):158-169.
-
Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial. Nat Med. 2024 Feb; 30(2):531-542.